{
  "contract_version": "supplier-contract-v0.1",
  "project": "col-901831",
  "supplier_group_id": "HENGXIANG",
  "generated_at": "2026-04-17T02:23:35.210Z",
  "model": "gpt-4.1-mini",
  "provider_stack": [
    "openai"
  ],
  "narratives": {
    "positioning_summary": "HENGXIANG 是 HS 9018312000 注射器品类中市场份额 2.14% 的 Tier A 供应商，活跃于 2012–2015 年。",
    "buyer_strategy": "其海外买家结构极度集中，Top1 买家 LIFE CARE SOLUTIONS S.A.S. 占比 83.9%，对替代者而言攻守难度极高。",
    "pricing_read": "其加权均价 $0.0281/unit 比市场均价 $0.0434/unit 低 35.1%，主战场在 $0.0294–$0.0360 档位，建议从 $0.0241–$0.0294 档位切入。",
    "trend_read": "其末年销量比峰值下滑 10%，海外买家净减 1 家，处于退场阶段。",
    "competitive_angles": {
      "strengths": [
        "Top1 买家 LIFE CARE SOLUTIONS S.A.S. 贡献 83.9% 营收",
        "出货批次达 97 批，供应链稳定性强"
      ],
      "weaknesses": [
        "价格比市场低 35.1%，利润空间被压缩",
        "Top1 买家依赖度过高，抗风险能力弱",
        "流失 1 家买家，客户粘性下降"
      ],
      "how_to_attack": "优先接触流失买家 HSC SAS, HEALTHCARE SOLUTIONS COLOMBIA SAS. 或体量次大的 IMPOMEDICAS DE COLOMBIA LTDA。报价切入 $0.0241–$0.0294 价格带，略低于其均价 $0.0281/unit。利用 75% 直接电汇的付款条件，配合 Buenaventura 港口偏好降低物流成本。"
    },
    "buyer_opportunities": [
      {
        "buyer": "HSC SAS, HEALTHCARE SOLUTIONS COLOMBIA SAS.",
        "angle": "流失",
        "action": "本周联系该买家，报价 $0.0241–$0.0294，强调其 2014 年销量从 $164K 跌至 $14K 后的恢复需求。"
      },
      {
        "buyer": "IMPOMEDICAS DE COLOMBIA LTDA",
        "angle": "Top 依赖",
        "action": "本周报价 $0.0294–$0.0360，利用其仅占供应商 7.3% 的份额，提出比 $0.0281/unit 更优的阶梯价。"
      },
      {
        "buyer": "LIFE CARE SOLUTIONS S.A.S.",
        "angle": "价格高位",
        "action": "本周试探性报价 $0.0294–$0.0360，针对其 83.9% 的依赖度，提供比市场均价 $0.0434/unit 低 10% 的试单价格。"
      }
    ]
  }
}